Research area combines AI and biomedicine in Dresden
The innovative research program “Biomedical Artificial Intelligence (AI) – BioAI Dresden” combines AI methods with biochemical and physical knowledge across the scales of biology and is expected to make a decisive contribution to a new scientific understanding of health.
Since November 2024, the Boehringer Ingelheim Foundation has been funding the newly established BioAI Dresden research field with 20 million euros over 10 years. The other half of the total 40 million euros for the joint project in the field of biological and biomedical AI will come from the Max Planck Society, the Dresden University of Technology (TU Dresden) and the German Federal State of Saxony.
"Living systems are extremely complex. AI will be the key to deciphering this complexity and understanding how living systems work. This exciting joint project will enable us to develop a new generation of physics-based biomedical AI algorithms to identify the principles and mechanisms that make up living systems. This puts us in an excellent position here at the site to drive the next revolution in the life sciences." Prof. Dr. Stephan Grill, Director of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden.
The new BioAI Dresden division with its two research groups is based at the Center for Systems Biology Dresden (CSBD) an inter-institutional center between the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), the Max Planck Institute for the Physics of Complex Systems (MPIPKS) and the Dresden University of Technology. In addition, BioAI Dresden will work in close partnership with the Boehringer Ingelheim Foundation-funded AITHYRA Institute in Vienna, which is also funded by the Boehringer Ingelheim Foundation.
The combination of biomedicine and artificial intelligence holds enormous potential that can only be exploited through comprehensive and interdisciplinary cooperation. Together, BioAI Dresden and the AITHYRA Institute partnerships with outstanding research institutions such as the European Molecular Biology Laboratory (EMBL) with its six sites in Europe, the EPFL - Swiss Federal Institute of Technology Lausanne, the University of Oxford and the Broad Institute in the USA. With the new research project, Dresden can make full use of its existing and future potential.
BioAI